Share Price and Basic Stock Data
Last Updated: November 8, 2025, 5:28 am
| PEG Ratio | 0.30 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Entero Healthcare Solutions Ltd operates within the pharmaceuticals industry, offering a range of healthcare solutions. As of recent reporting, the company’s share price stood at ₹1,112 with a market capitalization of ₹4,833 Cr. Entero recorded sales of ₹3,300 Cr for the fiscal year ending March 2023, which represented a significant growth trajectory from ₹2,522 Cr in March 2022 and ₹1,773 Cr in March 2021. The company’s revenues continued to grow, reaching ₹3,922 Cr in March 2024 and ₹5,096 Cr for the fiscal year ending March 2025. Quarterly sales figures indicate robust performance, with the latest quarter (September 2024) recording sales of ₹1,301 Cr. This consistent revenue growth reflects the company’s expanding market presence and product offerings, aligning with broader industry trends where pharmaceuticals are expected to maintain a steady growth rate, especially in the post-pandemic landscape.
Profitability and Efficiency Metrics
Entero Healthcare Solutions reported a net profit of ₹107 Cr for the fiscal year ending March 2025, a marked improvement from a loss of ₹11 Cr in March 2023. The company’s profitability metrics indicate a solid recovery, with an operating profit margin (OPM) that improved to 3% in March 2025 from 2% in March 2023. The return on equity (ROE) stood at 5.63%, showcasing effective use of shareholder funds. The interest coverage ratio (ICR) of 5.07x further emphasizes Entero’s ability to meet its interest obligations comfortably. However, the company’s operating profit remains modest relative to sector benchmarks, where leading firms often achieve OPMs exceeding 15%. The cash conversion cycle (CCC) of 80 days indicates a reasonable efficiency in managing working capital, although the pharmaceuticals sector typically aims for lower CCCs to enhance liquidity.
Balance Sheet Strength and Financial Ratios
As of March 2025, Entero Healthcare Solutions reported total assets of ₹2,703 Cr, against total liabilities of ₹2,703 Cr, reflecting a balanced balance sheet without significant leverage, as indicated by a total debt-to-equity ratio of 0.17. Reserves grew to ₹1,681 Cr, indicating a strengthening financial position. Borrowings stood at ₹385 Cr, down from ₹1,101 Cr in March 2023, showcasing the company’s efforts to reduce debt. The price-to-book value (P/BV) ratio of 2.87x suggests that the stock may be trading at a premium relative to its book value, which is typical for growth-oriented firms in the sector. However, the return on capital employed (ROCE) of 8.71% is relatively low compared to industry leaders, which often report ROCE figures above 15%, indicating potential room for operational improvement.
Shareholding Pattern and Investor Confidence
Entero’s shareholding structure reveals a strong promoter stake of 52.42%, which provides stability and confidence to investors. Foreign institutional investors (FIIs) held 17.21%, while domestic institutional investors (DIIs) accounted for 10.19% of the ownership. The public shareholding stood at 20.19%, with a total of 33,338 shareholders as of March 2025. The gradual decline in FII holdings from 23.30% in March 2024 to the current levels may indicate a cautious sentiment among foreign investors regarding growth prospects. However, the steady presence of promoters and increasing DII participation reflects a positive outlook among domestic investors. This ownership mix suggests a balanced investor confidence, which is crucial for the company’s future strategic initiatives and capital-raising endeavors.
Outlook, Risks, and Final Insight
Moving forward, Entero Healthcare Solutions is poised for growth, driven by its expanding revenue base and improving profitability metrics. However, risks such as fluctuating raw material costs and regulatory changes in the pharmaceutical sector could pose challenges to sustained profitability. The company’s ability to enhance its operating margins and return ratios will be critical in maintaining investor confidence and attracting further institutional investment. Additionally, the evolving competitive landscape in pharmaceuticals may require strategic adjustments to safeguard market share. If Entero can leverage its strengths while mitigating these risks effectively, it may unlock significant value for shareholders in the coming years, particularly if it can achieve operational efficiencies that align more closely with industry standards.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Entero Healthcare Solutions Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 137 Cr. | 109 | 247/84.3 | 31.1 | 46.7 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.63 Cr. | 1.90 | 4.33/1.90 | 0.57 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,906 Cr. | 450 | 479/192 | 110 | 22.8 | 0.15 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 36.9 Cr. | 25.2 | 29.1/17.0 | 38.5 | 6.83 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,608.79 Cr | 1,177.38 | 55.81 | 198.49 | 0.34% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 829 | 887 | 899 | 996 | 993 | 1,034 | 1,097 | 1,301 | 1,359 | 1,339 | 1,404 |
| Expenses | 810 | 867 | 873 | 968 | 964 | 1,005 | 1,067 | 1,258 | 1,309 | 1,290 | 1,354 |
| Operating Profit | 19 | 20 | 26 | 29 | 29 | 29 | 30 | 42 | 50 | 49 | 50 |
| OPM % | 2% | 2% | 3% | 3% | 3% | 3% | 3% | 3% | 4% | 4% | 4% |
| Other Income | 2 | 1 | 1 | 2 | 2 | 9 | 13 | 11 | 8 | 7 | 6 |
| Interest | 13 | 13 | 14 | 18 | 16 | 17 | 10 | 11 | 10 | 10 | 11 |
| Depreciation | 5 | 7 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 |
| Profit before tax | 2 | 1 | 7 | 7 | 8 | 14 | 27 | 35 | 39 | 37 | 36 |
| Tax % | -44% | 490% | 6% | 23% | 16% | -56% | 25% | 25% | 25% | 16% | 17% |
| Net Profit | 4 | -4 | 6 | 5 | 7 | 21 | 21 | 26 | 29 | 31 | 30 |
| EPS in Rs | 8.05 | -9.05 | 15.18 | 3.19 | 4.22 | 4.82 | 4.62 | 5.43 | 5.85 | 5.91 | 6.39 |
Last Updated: August 19, 2025, 3:47 pm
Below is a detailed analysis of the quarterly data for Entero Healthcare Solutions Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 1,404.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,339.00 Cr. (Mar 2025) to 1,404.00 Cr., marking an increase of 65.00 Cr..
- For Expenses, as of Jun 2025, the value is 1,354.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,290.00 Cr. (Mar 2025) to 1,354.00 Cr., marking an increase of 64.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 49.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 1.00 Cr..
- For OPM %, as of Jun 2025, the value is 4.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 4.00%.
- For Other Income, as of Jun 2025, the value is 6.00 Cr.. The value appears to be declining and may need further review. It has decreased from 7.00 Cr. (Mar 2025) to 6.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Jun 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 10.00 Cr. (Mar 2025) to 11.00 Cr., marking an increase of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 9.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.00 Cr. (Mar 2025) to 9.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 36.00 Cr.. The value appears to be declining and may need further review. It has decreased from 37.00 Cr. (Mar 2025) to 36.00 Cr., marking a decrease of 1.00 Cr..
- For Tax %, as of Jun 2025, the value is 17.00%. The value appears to be increasing, which may not be favorable. It has increased from 16.00% (Mar 2025) to 17.00%, marking an increase of 1.00%.
- For Net Profit, as of Jun 2025, the value is 30.00 Cr.. The value appears to be declining and may need further review. It has decreased from 31.00 Cr. (Mar 2025) to 30.00 Cr., marking a decrease of 1.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 6.39. The value appears strong and on an upward trend. It has increased from 5.91 (Mar 2025) to 6.39, marking an increase of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:24 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 1,350 | 1,773 | 2,522 | 3,300 | 3,922 | 5,096 | 5,403 |
| Expenses | 1,326 | 1,758 | 2,498 | 3,236 | 3,810 | 4,924 | 5,211 |
| Operating Profit | 23 | 15 | 24 | 64 | 112 | 172 | 191 |
| OPM % | 2% | 1% | 1% | 2% | 3% | 3% | 4% |
| Other Income | 5 | 11 | 4 | 6 | 14 | 39 | 32 |
| Interest | 13 | 20 | 29 | 49 | 66 | 42 | 43 |
| Depreciation | 12 | 16 | 20 | 24 | 25 | 31 | 33 |
| Profit before tax | 4 | -11 | -20 | -4 | 36 | 139 | 148 |
| Tax % | 67% | 42% | 49% | 201% | -12% | 23% | |
| Net Profit | 1 | -15 | -29 | -11 | 40 | 107 | 117 |
| EPS in Rs | 93.81 | -1,550.90 | -77.71 | -28.12 | 8.99 | 21.80 | 23.58 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -1600.00% | -93.33% | 62.07% | 463.64% | 167.50% |
| Change in YoY Net Profit Growth (%) | 0.00% | 1506.67% | 155.40% | 401.57% | -296.14% |
Entero Healthcare Solutions Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 30% |
| 3 Years: | 26% |
| TTM: | 31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 152% |
| 3 Years: | 73% |
| TTM: | 94% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -17% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 6% |
Last Updated: September 5, 2025, 3:26 pm
Balance Sheet
Last Updated: September 10, 2025, 3:36 pm
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.10 | 0.10 | 4 | 4 | 43 | 44 |
| Reserves | -16 | -32 | -62 | -73 | 1,595 | 1,681 |
| Borrowings | 603 | 720 | 974 | 1,101 | 338 | 385 |
| Other Liabilities | 162 | 147 | 210 | 275 | 369 | 593 |
| Total Liabilities | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 |
| Fixed Assets | 186 | 189 | 262 | 268 | 289 | 559 |
| CWIP | 2 | 2 | 1 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 58 |
| Other Assets | 560 | 645 | 863 | 1,040 | 2,056 | 2,085 |
| Total Assets | 749 | 836 | 1,125 | 1,308 | 2,345 | 2,703 |
Below is a detailed analysis of the balance sheet data for Entero Healthcare Solutions Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 44.00 Cr.. The value appears strong and on an upward trend. It has increased from 43.00 Cr. (Mar 2024) to 44.00 Cr., marking an increase of 1.00 Cr..
- For Reserves, as of Mar 2025, the value is 1,681.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,595.00 Cr. (Mar 2024) to 1,681.00 Cr., marking an increase of 86.00 Cr..
- For Borrowings, as of Mar 2025, the value is 385.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 338.00 Cr. (Mar 2024) to 385.00 Cr., marking an increase of 47.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 593.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 369.00 Cr. (Mar 2024) to 593.00 Cr., marking an increase of 224.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 2,703.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2,345.00 Cr. (Mar 2024) to 2,703.00 Cr., marking an increase of 358.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 559.00 Cr.. The value appears strong and on an upward trend. It has increased from 289.00 Cr. (Mar 2024) to 559.00 Cr., marking an increase of 270.00 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 58.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 58.00 Cr., marking an increase of 58.00 Cr..
- For Other Assets, as of Mar 2025, the value is 2,085.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,056.00 Cr. (Mar 2024) to 2,085.00 Cr., marking an increase of 29.00 Cr..
- For Total Assets, as of Mar 2025, the value is 2,703.00 Cr.. The value appears strong and on an upward trend. It has increased from 2,345.00 Cr. (Mar 2024) to 2,703.00 Cr., marking an increase of 358.00 Cr..
Notably, the Reserves (1,681.00 Cr.) exceed the Borrowings (385.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -580.00 | -705.00 | -950.00 | 63.00 | -226.00 | -213.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 63 | 50 | 54 | 57 | 57 | 59 |
| Inventory Days | 57 | 54 | 49 | 41 | 43 | 52 |
| Days Payable | 32 | 22 | 22 | 25 | 24 | 31 |
| Cash Conversion Cycle | 88 | 82 | 81 | 73 | 77 | 80 |
| Working Capital Days | 57 | 54 | 41 | 32 | 48 | 65 |
| ROCE % | 1% | 1% | 5% | 7% | 9% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 21.80 | 10.81 | -3.10 | -9.22 | -5.29 |
| Diluted EPS (Rs.) | 21.76 | 10.81 | -3.10 | -9.22 | -5.29 |
| Cash EPS (Rs.) | 31.75 | 14.90 | 31.94 | -25.16 | 92.20 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 396.28 | 377.38 | -160.39 | -144.87 | -3005.20 |
| Revenue From Operations / Share (Rs.) | 1171.23 | 901.80 | 8025.80 | 6550.82 | 177973.70 |
| PBDIT / Share (Rs.) | 48.51 | 29.03 | 169.07 | 75.12 | 2547.60 |
| PBIT / Share (Rs.) | 41.45 | 23.28 | 110.13 | 23.81 | 920.00 |
| PBT / Share (Rs.) | 31.89 | 8.17 | -8.97 | -51.46 | -1083.80 |
| Net Profit / Share (Rs.) | 24.69 | 9.15 | -27.00 | -76.46 | -1535.40 |
| NP After MI And SOA / Share (Rs.) | 21.79 | 8.99 | -28.11 | -77.71 | -1553.70 |
| PBDIT Margin (%) | 4.14 | 3.21 | 2.10 | 1.14 | 1.43 |
| PBIT Margin (%) | 3.53 | 2.58 | 1.37 | 0.36 | 0.51 |
| PBT Margin (%) | 2.72 | 0.90 | -0.11 | -0.78 | -0.60 |
| Net Profit Margin (%) | 2.10 | 1.01 | -0.33 | -1.16 | -0.86 |
| NP After MI And SOA Margin (%) | 1.86 | 0.99 | -0.35 | -1.18 | -0.87 |
| Return on Networth / Equity (%) | 5.49 | 2.38 | 0.00 | 0.00 | 0.00 |
| Return on Capital Employeed (%) | 9.70 | 5.80 | 6.61 | 1.38 | 1.68 |
| Return On Assets (%) | 3.50 | 1.66 | -0.88 | -2.65 | -1.86 |
| Long Term Debt / Equity (X) | 0.00 | 0.02 | -0.45 | -0.64 | 0.00 |
| Total Debt / Equity (X) | 0.17 | 0.16 | -5.45 | -4.92 | -4.46 |
| Asset Turnover Ratio (%) | 2.02 | 2.15 | 2.71 | 2.57 | 0.00 |
| Current Ratio (X) | 2.46 | 3.34 | 1.64 | 1.84 | 2.19 |
| Quick Ratio (X) | 1.68 | 2.64 | 1.09 | 1.17 | 1.35 |
| Inventory Turnover Ratio (X) | 9.43 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | 5.07 | 1.92 | 1.42 | 0.99 | 1.27 |
| Interest Coverage Ratio (Post Tax) (X) | 3.58 | 1.61 | 0.77 | -0.01 | 0.23 |
| Enterprise Value (Cr.) | 5029.50 | 3669.42 | 0.00 | 0.00 | 0.00 |
| EV / Net Operating Revenue (X) | 0.98 | 0.93 | 0.00 | 0.00 | 0.00 |
| EV / EBITDA (X) | 23.83 | 29.06 | 0.00 | 0.00 | 0.00 |
| MarketCap / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| Price / BV (X) | 2.87 | 2.62 | 0.00 | 0.00 | 0.00 |
| Price / Net Operating Revenue (X) | 0.97 | 1.09 | 0.00 | 0.00 | 0.00 |
| EarningsYield | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 |
After reviewing the key financial ratios for Entero Healthcare Solutions Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 21.80. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.80, marking an increase of 10.99.
- For Diluted EPS (Rs.), as of Mar 25, the value is 21.76. This value is within the healthy range. It has increased from 10.81 (Mar 24) to 21.76, marking an increase of 10.95.
- For Cash EPS (Rs.), as of Mar 25, the value is 31.75. This value is within the healthy range. It has increased from 14.90 (Mar 24) to 31.75, marking an increase of 16.85.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 396.28. It has increased from 377.38 (Mar 24) to 396.28, marking an increase of 18.90.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1,171.23. It has increased from 901.80 (Mar 24) to 1,171.23, marking an increase of 269.43.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 48.51. This value is within the healthy range. It has increased from 29.03 (Mar 24) to 48.51, marking an increase of 19.48.
- For PBIT / Share (Rs.), as of Mar 25, the value is 41.45. This value is within the healthy range. It has increased from 23.28 (Mar 24) to 41.45, marking an increase of 18.17.
- For PBT / Share (Rs.), as of Mar 25, the value is 31.89. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 31.89, marking an increase of 23.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 24.69. This value is within the healthy range. It has increased from 9.15 (Mar 24) to 24.69, marking an increase of 15.54.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 21.79. This value is within the healthy range. It has increased from 8.99 (Mar 24) to 21.79, marking an increase of 12.80.
- For PBDIT Margin (%), as of Mar 25, the value is 4.14. This value is below the healthy minimum of 10. It has increased from 3.21 (Mar 24) to 4.14, marking an increase of 0.93.
- For PBIT Margin (%), as of Mar 25, the value is 3.53. This value is below the healthy minimum of 10. It has increased from 2.58 (Mar 24) to 3.53, marking an increase of 0.95.
- For PBT Margin (%), as of Mar 25, the value is 2.72. This value is below the healthy minimum of 10. It has increased from 0.90 (Mar 24) to 2.72, marking an increase of 1.82.
- For Net Profit Margin (%), as of Mar 25, the value is 2.10. This value is below the healthy minimum of 5. It has increased from 1.01 (Mar 24) to 2.10, marking an increase of 1.09.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.86. This value is below the healthy minimum of 8. It has increased from 0.99 (Mar 24) to 1.86, marking an increase of 0.87.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.49. This value is below the healthy minimum of 15. It has increased from 2.38 (Mar 24) to 5.49, marking an increase of 3.11.
- For Return on Capital Employeed (%), as of Mar 25, the value is 9.70. This value is below the healthy minimum of 10. It has increased from 5.80 (Mar 24) to 9.70, marking an increase of 3.90.
- For Return On Assets (%), as of Mar 25, the value is 3.50. This value is below the healthy minimum of 5. It has increased from 1.66 (Mar 24) to 3.50, marking an increase of 1.84.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.02 (Mar 24) to 0.00, marking a decrease of 0.02.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.16 (Mar 24) to 0.17, marking an increase of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 2.02. It has decreased from 2.15 (Mar 24) to 2.02, marking a decrease of 0.13.
- For Current Ratio (X), as of Mar 25, the value is 2.46. This value is within the healthy range. It has decreased from 3.34 (Mar 24) to 2.46, marking a decrease of 0.88.
- For Quick Ratio (X), as of Mar 25, the value is 1.68. This value is within the healthy range. It has decreased from 2.64 (Mar 24) to 1.68, marking a decrease of 0.96.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 9.43. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 9.43, marking an increase of 9.43.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 5.07. This value is within the healthy range. It has increased from 1.92 (Mar 24) to 5.07, marking an increase of 3.15.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 3.58. This value is within the healthy range. It has increased from 1.61 (Mar 24) to 3.58, marking an increase of 1.97.
- For Enterprise Value (Cr.), as of Mar 25, the value is 5,029.50. It has increased from 3,669.42 (Mar 24) to 5,029.50, marking an increase of 1,360.08.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.98. This value is below the healthy minimum of 1. It has increased from 0.93 (Mar 24) to 0.98, marking an increase of 0.05.
- For EV / EBITDA (X), as of Mar 25, the value is 23.83. This value exceeds the healthy maximum of 15. It has decreased from 29.06 (Mar 24) to 23.83, marking a decrease of 5.23.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 2.87. This value is within the healthy range. It has increased from 2.62 (Mar 24) to 2.87, marking an increase of 0.25.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.97. This value is below the healthy minimum of 1. It has decreased from 1.09 (Mar 24) to 0.97, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.01. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Entero Healthcare Solutions Ltd:
- Net Profit Margin: 2.1%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 9.7% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.49% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 3.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.68
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 46.2 (Industry average Stock P/E: 55.81)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.17
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.1%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. I-35, Building - B, Industrial Area, Phase - I, Faridabad Haryana 121003 | info@enterohealthcare.com http://www.enterohealthcare.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Sujesh Vasudevan | Chairperson (NonExe.&Ind.Director) |
| Mr. Prabhat Agrawal | Managing Director & CEO |
| Mr. Prem Sethi | Whole Time Director & COO |
| Mr. Rajesh Shashikant Dalal | Ind. Non-Executive Director |
| Ms. Sandhya Gadkari Sharma | Ind. Non-Executive Director |
| Mr. Arun Sadhanandham | Non Exe.Non Ind.Director |
| Ms. Sumona Chakraborty | Non Exe.Non Ind.Director |
| Mr. Kevin Rohitbhai Daftary | Non Exe.Non Ind.Director |
FAQ
What is the intrinsic value of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd's intrinsic value (as of 08 November 2025) is 840.50 which is 22.82% lower the current market price of 1,089.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 4,739 Cr. market cap, FY2025-2026 high/low of 1,565/1,038, reserves of ₹1,681 Cr, and liabilities of 2,703 Cr.
What is the Market Cap of Entero Healthcare Solutions Ltd?
The Market Cap of Entero Healthcare Solutions Ltd is 4,739 Cr..
What is the current Stock Price of Entero Healthcare Solutions Ltd as on 08 November 2025?
The current stock price of Entero Healthcare Solutions Ltd as on 08 November 2025 is 1,089.
What is the High / Low of Entero Healthcare Solutions Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Entero Healthcare Solutions Ltd stocks is 1,565/1,038.
What is the Stock P/E of Entero Healthcare Solutions Ltd?
The Stock P/E of Entero Healthcare Solutions Ltd is 46.2.
What is the Book Value of Entero Healthcare Solutions Ltd?
The Book Value of Entero Healthcare Solutions Ltd is 396.
What is the Dividend Yield of Entero Healthcare Solutions Ltd?
The Dividend Yield of Entero Healthcare Solutions Ltd is 0.00 %.
What is the ROCE of Entero Healthcare Solutions Ltd?
The ROCE of Entero Healthcare Solutions Ltd is 8.71 %.
What is the ROE of Entero Healthcare Solutions Ltd?
The ROE of Entero Healthcare Solutions Ltd is 5.63 %.
What is the Face Value of Entero Healthcare Solutions Ltd?
The Face Value of Entero Healthcare Solutions Ltd is 10.0.